Burden of Disease in the Real-Life Setting of Patients with Atopic Dermatitis: Italian Data From the MEASURE-AD Study

Giuseppe Argenziano¹, Santo Raffaele Mercuri², Paola Savoia³, Paolo Amerio⁴, Anna Belloni Fortina⁵, Maria Rita Bongiorno⁶, Maria Beatrice De Felici Del Giudice⁷, Aurora Parodi⁸, Nicola Pimpinelli⁹, Luca Stingeni¹⁰, Michela Ortoncelli¹¹, Giuseppe Stinco¹², Giuliana Gualberti¹³, Anna Levi¹³, Valeria Scuderi¹³, Luca Bianchi¹⁴, Giovanna Malara¹⁵

1 Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
2 Unit of Dermatology, IRCCS San Raffaele Hospital, Milan, Italy
3 Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy
4 Dermatologic Clinic, Department of Medicine and Aging Science and Dermatologic Clinic, University “G. d’Annunzio”, Chieti-Pescara, Chieti, Italy
5 Unit of Pediatric Dermatology, Department of Medicine DIMED, University of Padua, Padua, Italy
6 Section of Dermatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medicine Specialties, University of Palermo, Palermo, Italy
7 Dermatologic Unit, University Hospital of Parma, Department of Medicine and Surgery, Parma, Italy
8 Division of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, Genoa Italy and Ospedale Policlinico San Martino IRCCS, Genoa, Italy
9 Dermatology Unit, Department Health Sciences, University of Florence, Florence, Italy
10 Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
11 Medical Sciences Department, Dermatologic Clinic, University of Turin, Turin, Italy
12 Institute of Dermatology, University of Udine, Udine, Italy
13 AbbVie SrL, Campoverde di Latina, Italy
14 Dermatology Unit, Tor Vergata University Hospital, Rome, Italy
15 UOC of Dermatology, Grande Ospedale Metropolitano “Bianchi Melacrino Morelli”, Reggio Calabria, Italy

Key words: real-life, moderate-to-severe atopic dermatitis, burden, QoL measures


Accepted: September 24, 2023; Published: January 2024

Copyright: ©2024 Argenziano et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.

Funding: AbbVie sponsored the study, participated in data collection, analysis, and interpretation of the data, in writing, reviewing and approval of the publication. No honoraria or payments were made for the publication.

Competing Interests: Paolo Amerio has received honoraria and speaker fees for: AbbVie, Janssen, Novartis, Sanofi, Amgen. Anna Belloni Fortina has served as consultant and/or participated to advisory boards for Abbvie, Sanofi, Novartis, Cilag Janssen, Leopharma, Pfizer and Artsana. Nicola Pimpinelli has the following conflicts of interest to disclose: BMS (unrestricted educational grant), Kiyowa Kirin (advisory board, unrestricted educational grant), Novartis (research grant), Pierre Fabre (speakers’ bureau), Recordati Rare Diseases (speakers’ bureau, unrestricted educational grant), Sanofi (speakers’ bureau), Takeda (advisory board, unrestricted educational grant). Michela Ortoncelli has participated to advisory board and events for Abbvie, Sanofi, Lilly, Novartis, Leo Pharma. Aurora Parodi has participated to clinical studies for Abbvie, Almirall, Galderma, Pfizer, Novartis, Leo pharma, Eli Lilly, Amgen, UCB. Luca Stingeni has been principal investigator in clinical trials sponsored by and/or and has received personal fees from Abbvie, Celgene, Janssen, LeoPharma, Lilly, Novartis, Regeneron, Sanofi, outside the submitted work. Luca Bianchi has served as speaker and consultant for Abbvie, Novartis, Janssen-Cilag, Pfizer, UCB, Biogen, Leopharma, Sanofi, Eli Lilly, Sun Pharma, Santpharma outside the submitted work. Giuliana Gualberti and Anna Levi

Original Article | Dermatol Pract Concept. 2024;14(1):e2024079
ABSTRACT

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease that negatively impacts the quality of life and work productivity of patients.

Objectives: We sought to evaluate the real-world burden of AD patients in Italy.

Methods: This sub-analysis of the MEASURE-AD multicountry study conducted between December 2019-2020 included patients diagnosed with moderate-to-severe AD eligible for receiving systemic therapy in the previous 6 months. During a single visit, physician and patient-reported questionnaires were used.

Results: A total of 118 adult patients were enrolled and 57.6% (N = 68) of patients had moderate-to-severe AD at the time of enrolment according to the Eczema Area and Severity Index. Sleep disorders interfered with daily function in the previous week in 58.5% (N = 69) of patients, pruritus was severe in 50% (N = 59) and 42.4% (N = 50) reported a flare lasting >7 days in the previous 6 months. According to the Dermatology Quality of Life Index, 37.3% (N = 44) of patients reported a severe impact of AD and approximately 10% had clinical depression/anxiety. Current drug therapy was considered inadequate in controlling AD in 26.3% (N=31) of patients. Work activity impairment was 38.6±31.7% and monthly AD-related expenses were 148.6±134.6 Euros per patient.

Conclusions: This real-life study documents a high burden of disease in patients with moderate-severe AD in Italy.

Introduction

Atopic dermatitis (AD) is a chronic, inflammatory, skin disorder associated with significant disease burden. The burden of AD mainly derives from signs and symptoms of AD which cause severe sleep loss in the first instance, then subsequently has a strong impact on quality of life (QoL), leading to the development of pathologies/conditions such as mental health disturbance, anxiety and depression as well as work/study impairment [1,2].

Consensus based European guidelines recommend that adults with severe AD whose symptoms are not adequately controlled with topical agents should be considered for systemic treatments as well as immunosuppressants, phototherapy, or short-term oral corticosteroids for the management of acute flares [3]. Systemic therapy can be useful to reduce the total amount of topical corticosteroids in patients who need large amounts of potent topical corticosteroids for large body areas over prolonged periods to control their AD.

Indeed, the area of systemic therapy for the treatment of AD has flourished in the past few years, as many new substances (including inhibitors of IL-4 and IL-13 signaling pathways as well as Janus kinase; JAK inhibitors) have been marketed, licensed, or are in the last stages of clinical development [3–5]. Development programs for these novel biologics are providing much better levels of evidence compared to older traditional drugs.

Substantial gaps in our understanding remain with regards to the overall burden of AD on patient health and wellbeing, particularly in patients with moderate-to-severe disease [6–9]. Recent studies in moderate-to-severe AD report the presence of a multidimensional disease burden [10–13] that includes other atopic comorbidities associated with pruritus such as sleep disturbance and functional impairment, and secondary consequences including neuropsychiatric issues (anxiety, depression) and reduced health related QoL (HRQoL) [1,14–16].

Nevertheless, few studies worldwide have specifically examined the burden of moderate-to-severe AD across a wide spectrum of QoL measures, particularly from the patients perspective [11,13,17–22].

Objectives

To address these gaps, this sub-analysis of the global cross-sectional MEASURE-AD study was performed on the
adult population in Italy to collect information on disease burden experienced by patients in terms of itching, skin pain, sleep and mental disturbance as well as work productivity and out-of-pocket expenses.

Methods

Study Design
The MEASURE-AD study is a multicenter, cross-sectional, observational study of patients with moderate-to-severe AD that aimed to assess the multidimensional burden of disease, treatment pattern, and health care resources. This sub-analysis of the MEASURE-AD study performed in Italy evaluated AD patients enrolled between December 2019 and December 2020 in a real-world setting.

Patients
Patients attending a routine visit, who fulfilled the following selection criteria were included: a confirmed diagnosis of AD in patients aged ≥18 years with moderate-to-severe AD, patients who are (i) current candidates for systemic therapy for AD, or (ii) currently receiving systemic therapy for AD, treatment history for the past 6 months; able to understand the questionnaires, consent to use and disclose personal health information and to participate in the study. Patients were excluded if they were currently participating in interventional clinical trial(s). The study was conducted in accordance with the declaration of Helsinki and approval was obtained by all the Local Ethics Committees (first approval from Comitato Etico Università degli Studi della Campania “Luigi Vanvitelli”, Prot N.: 766, on 05/12/2019).

Outcome Measures

Disease Severity
The extent and severity of AD were evaluated by dermatologists through the Eczema Area and Severity Index (EASI) [23,24] score according to Chopra [25] and Leshem [24]. Patients self-reported AD symptoms through the Patient-Reported Eczema Measure (POEM) [26].

Itching/Pruritus
Numerical Rating Scales (0–10) for pruritus (Itch-NRS) and the 5-D pruritus scale were used to assess the level of pruritus [27,28].

Skin Pain
The ADerm-SS questionnaire was used to assess patient-reported skin pain [29].

Impact of AD on HRQoL
AD impact on health-related QoL was self-evaluated by patients through the Dermatology Quality of Life Index (DLQI) [30].

Patient-Reported Disease Control
Patient-reported disease control was assessed by asking patients to rate their degree of agreement with the validated statement, “I feel my current treatments are effective in controlling my atopic dermatitis.” Patients were also asked to report the number and average duration of AD flares in the previous 6 months.

Patient-Reported Sleep
Specific sleep-related questions were used to assess the impact of AD on sleep. These included: 1) average number of hours slept per night in the past week, 2) average number of minutes needed to fall asleep per night in the past week, 3) number of nights in which sleep was disturbed over the past week, 4) sleep problems that interfered with daily function over the past week, 5) sleep problems that interfered with daily function over the past week.

The Atopic Dermatitis Impact Scale (ADerm-IS) questionnaire was also used to assess the impact of AD on sleep, daily activities and emotion [29].

Patient-Reported Mental Health
The Hospital Anxiety and Depression Scale (HADS) was used to assess Symptoms of anxiety and depression [31].

Impact of AD on Work Productivity
The Work Productivity and Activity Impairment Questionnaire–Atopic Dermatitis (WPAI-AD) was used to measure impairment due to AD [32,33]. Scores were calculated as percentages, with higher scores indicating greater work productivity loss and activity impairment.

Out-of-Pocket Expenses
Patients documented their treatment and other healthcare-related expenses each month (in Euro) due to their AD.

Statistical Analysis
Data are presented as mean and standard deviation for normally distributed variables or number and % for categorical variables. Statistical analysis was performed using SAS® Software (release 9.4, SAS Institute) on Microsoft Windows.

Results

Patient Characteristics
Baseline demographic and clinical characteristics of the study population are summarized in Table 1. Sixty-three (53.4%) patients were male and mean age was 37.7±15.4 years. The mean age at disease onset was 13.3±17.9 years and a family history of AD was seen in 44.1% (N =52) of patients. Most patients also had atopic comorbidities (78.8%; N = 93), the
most frequent being allergic rhinitis (48.3%; N = 57) or allergic asthma (33.9%; N = 40). Non-atopic comorbidities were also seen in approximately one-third of patients (33.9%; N = 40), the most frequent being hypertension, (12.5%; N = 15), anxiety (11.9%; N = 14), depression and diabetes (both 4.2%; N = 5).

Current Treatment
The average time taken from diagnosis of AD to first treatment was 139±177.4 months and to first systemic treatment was 231±169.4 months. Four patients (3.4%) were not receiving any treatment, while 53 patients (44.9%) were receiving topical treatment (Table 1). However, most patients (77.1%; N = 91) were currently receiving systemic treatment. Just over half of patients were being currently prescribed dupilumab (56.8%; N = 67), administered alone in 38 (32.2%) patients, in combination with topical therapy in 17 patients (14.4%) or in combination with topical and another systemic therapy in 1 (0.8%) patient.

Outcome Measures
Disease Severity
Mean EASI score was 11.2±11.5 (Table 1) and 57.6% (N = 68) patients were categorized as having moderate-to-severe AD according to Chopra (Figure 1A) while 53.4% (N = 63) patients were categorized as having moderate-to-severe AD according to Leshem (Figure 1B). Mean body surface area (BSA) was 18.7±20.3% (Table 1) and 40.7% (N = 48) of patients were categorized as having moderate-to-severe AD according to Chopra BSA AD severity (Figure 1C) [25].

Sleep and the Impact of Itching/Pruritus
The average number of hours slept per night in the past week was 6.5±1.7 and the average time needed to fall asleep per night was 31.1±31.7 minutes. In the past week, the average number of days with disturbed sleep was 2.7±2.5 days and in 58.5% of patients (N = 69) sleep problems interfered with daily function (Figure 2A).

The patient-reported 5D pruritus scale revealed that 33.1% (N = 39) patients experienced delays falling asleep due to pruritus (Figure 2B).

Question 2 from the POEM questionnaire “Over the last week, on how many nights has your sleep been disturbed because of your eczema?” revealed that as many as 41.5% (N = 49) patients had disturbed sleep due to eczema (Figure 2C).

Mean scores for sleep, daily activities and emotional state domains according to the ADerm-IS questionnaire were similar (ranging from 11.8 to 13.9) and the total ADerm-IS score was 37.5±30.4 (Table 2). In terms of ADerm-IS single item scores, items relating to sleep disturbance were generally higher compared to other items evaluated.

Mean Itch-NRS was 5.4±3.4 and 65.3% (N = 77) of patients reported moderate or severe pruritus according to Vakharia scale (Figure 3A) [27].

Question 1 from the POEM questionnaire “Over the last week, on how many days has your skin been itchy because of your eczema?” showed that the majority of patients were affected by itch skin because of their eczema in the past week and 65.3% (N = 77) were itchy ≥3 days in the past week (Figure 3B).

Skin Pain
Mean score for ADerm-TSS-7 and ADerm-TSS-11 were 32.4±21.9 and 47.8±33.5 respectively (Table 3). Lowest mean scores for quantitative variables evaluated were from 4 (worst skin cracking) to highest of 5.4 (worst dry skin) and worst skin pain categories (7-10) accounted for 33.9%
AD on DLQI were 41.5% (N = 49), 21.2% (N = 25) and 37.3% (N = 44) respectively. In general, in >50% of patients, AD affected (a little or a lot/much) a physical, social, emotional, and personal issues for a wide range of DLQI items. The proportion of patients responding to the item “itchy, sore, painful, stinging skin” were 10.8%, 39.2% and 45.8% for “not at all”, “a little” or “a lot/very much” respectively.

**Patient-Reported Disease Control and Presence of Flares**

For 68 (57.6%) patients their current drug therapy was considered effective, while 31 (26.3%) patients felt their therapy less effective. AD = atopic dermatitis; POEM = Patient-Reported Eczema Measure.

AD on DLQI were 41.5% (N = 49), 21.2% (N = 25) and 37.3% (N = 44) respectively. In general, in >50% of patients, AD affected (a little or a lot/much) a physical, social, emotional, and personal issues for a wide range of DLQI items. The proportion of patients responding to the item “itchy, sore, painful, stinging skin” were 10.8%, 39.2% and 45.8% for “not at all”, “a little” or “a lot/very much” respectively.

**Impact of AD on HRQoL**

Overall mean DLQI score was 8.7±7.3 and the proportion of patients reporting a mild, moderate and severe impact of AD on DLQI were 41.5% (N = 49), 21.2% (N = 25) and 37.3% (N = 44) respectively. In general, in >50% of patients, AD affected (a little or a lot/much) a physical, social, emotional, and personal issues for a wide range of DLQI items. The proportion of patients responding to the item “itchy, sore, painful, stinging skin” were 10.8%, 39.2% and 45.8% for “not at all”, “a little” or “a lot/very much” respectively.

For 68 (57.6%) patients their current drug therapy was considered effective, while 31 (26.3%) patients felt that...
Table 2. Results for ADerm-IS

<table>
<thead>
<tr>
<th>Variable</th>
<th>mean±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quantitative variables</strong></td>
<td></td>
</tr>
<tr>
<td>Sleep domain score</td>
<td>11.9±10.2</td>
</tr>
<tr>
<td>Daily activities domain score</td>
<td>13.9±12.3</td>
</tr>
<tr>
<td>Emotional state domain score</td>
<td>11.8±10.3</td>
</tr>
<tr>
<td>ADerm-IS total score</td>
<td>37.5±30.4</td>
</tr>
<tr>
<td><strong>ADerm-IS single items</strong></td>
<td></td>
</tr>
<tr>
<td>Difficulty falling asleep due to AD</td>
<td>3.7±3.3</td>
</tr>
<tr>
<td>Impact of AD on sleep</td>
<td>3.8±3.5</td>
</tr>
<tr>
<td>Bothered at night due to AD</td>
<td>4.4±3.9</td>
</tr>
<tr>
<td>AD limiting household activities</td>
<td>3.7±3.5</td>
</tr>
<tr>
<td>AD limiting physical activities</td>
<td>3.3±3.3</td>
</tr>
<tr>
<td>AD limiting social activities</td>
<td>3.3±3.4</td>
</tr>
<tr>
<td>Difficulty concentrating due to AD</td>
<td>3.7±3.3</td>
</tr>
<tr>
<td>Self-consciousness due to AD</td>
<td>4.0±3.6</td>
</tr>
<tr>
<td>Embarrassment due to AD</td>
<td>3.8±3.5</td>
</tr>
<tr>
<td>Sadness due to AD</td>
<td>4.1±3.8</td>
</tr>
</tbody>
</table>

The questionnaire was composed of 3 domains (sleep, daily activities and emotion) and an overall score as well as 10 single items (questions) based on the 3 domains. Three questions assessed the impact of AD over the previous 24 hours and 7 questions assessed the impact over the past 7 days. Sleep domain score = questions 1-3, Daily activities domain score = questions 4-7 and Emotional state domain score: questions 8-10. ADerm-IS total score: questions 1-10.

Each question displays a rating scale of answer options ranging from 0 to 10 with a higher score indicating a larger (negative) impact. Each score was calculated as sum of the contributing items. If a contributing value was missing the score could not be calculated.

AD = atopic dermatitis; SD = standard deviation.

Figure 3. The extent of itching/pruritus experienced by patients with AD. (A) Proportion of patients categorized as having mild, moderate or severe pruritus according to NRS Vakharia scale. (B) Proportion of patients categorized by the number of days that they were affected by their pruritus in the past week according to question 1 of POEM questionnaire; “Over the last week, on how many days has your skin been itchy because of your eczema?”. The level of pruritus was assessed in the following NRS categories according to Vakharia: mild: 0-3, moderate: 4-6 and severe: 7-10. The 5-D pruritus scale was a multidimensional questionnaire to measure itch. The five dimensions are duration, degree, direction, disability and distribution. 5-D scores ranged from 5 (no pruritus) to 25 (most severe pruritus). Data are presented as %.

AD = atopic dermatitis; NRS = Numerical Rating Scales; POEM = Patient-Reported Eczema Measure.

Impact of AD on Work Productivity

Of the proportion of patients that were currently employed (N = 62; 52.5%), a mean presenteeism of 32.8±29.6%, mean absenteeism of 7.1±18.1% and a mean overall work productivity impairment of 36.1±30.9% were reported. The mean number of hours missed from work in the past 7 days was 1.7±5.6. Overall work activity impairment on daily life was 38.6±31.7%.

Out-of-Pocket Expenses

Monthly healthcare-related expenses and monthly costs for everyday necessities due to AD were 90.1±93.9 Euro and 56.7±63.1 Euro respectively with total monthly expenses of 148.6±134.7 Euro equating to 0.72±0.9% of annual family income.

Discussion

In AD, it is recognized that increased disease severity is frequently correlated with a worsening in QoL of the
or severe in 21.2% or 37.3%, respectively. Similarly, about one-third of patients were judged as having clear or mild disease (by EASI) corresponding to a similar proportion of patients reporting no impact of their AD on sleep, pruritus or QoL measures.

Previous real-life studies in Italy have recently evaluated the association of factors affecting QoL in AD patients [17,20,21,35,36]. Ferrucci and colleagues evaluated factors associated with poor QoL in 300 AD patients with severe disease (mean EASI was 29.45±7.1 and DLQI was 16.8±6.8) [35]. Poor quality of sleep was found to be a predictor of anxiety symptoms, which is not surprising as anxiety disorders are frequently associated with insomnia [37]. Approximately half of patients had clinical anxiety or depressive symptoms (considering a HADS of ≥8) compared to approximately 30% in our study, likely reflecting the difference in the severity of AD in patients in their cohort. Similarly, in their study, poor sleep, itch and depression were correlated with each other, which again is to be expected and in turn to negatively impact upon daily activities and consequently QoL [38]. These results corroborate with observations by Miniotti et al where POEM, NRS for pruritus and sleep disturbance were significantly associated with DLQI and also in a small study by Milanesi et al where itch severity positively correlated with sleep quality [17,21].

In a post-hoc analysis of two randomized placebo-controlled phase-3 trials, Offidani et al., evaluated the improvement in signs and symptoms and QoL in patients with an EASI score of ≥20 to <24 or ≥24 treated with dupilumab for 16 weeks [36]. A weak correlation at baseline was observed between physician-assessed outcomes (reflected by EASI), patient-reported symptoms and QoL (reflected by pruritus NRS and DLQI) suggesting that patients with baseline EASI score of 20-24 can have substantial burden of disease and poor QoL. Indeed, patients with a substantially lower EASI (such as 11.2±11.5 in our study) can still be significantly burdened by their AD.

The impact of AD on work productivity observed in our study confirm evidence from previous studies of AD [39–41]. Indeed, we observed that the proportion of patients with moderate (~30%) or severe (~20%) disease by the EASI or BSA closely reflect the proportion of patient with worse reported outcomes such as the proportion of patients affected by sleep problems (58.8%), severe pruritus (50.0%) and reporting a flare in the past week (42.4%). According to the DLQI, the impact of AD was reported to be moderate or severe in 21.2% or 37.3%, respectively. Similarly, about one-third of patients were judged as having clear or mild disease (by EASI) corresponding to a similar proportion of patients reporting no impact of their AD on sleep, pruritus or QoL measures.

Table 3. Results for ADerm-SS.

<table>
<thead>
<tr>
<th>Variable</th>
<th>mean±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADerm-TSS-7 score</td>
<td>32.4±21.9</td>
</tr>
<tr>
<td>ADerm-TSS-11 score</td>
<td>47.8±33.5</td>
</tr>
<tr>
<td>ADerm-SS single items</td>
<td></td>
</tr>
<tr>
<td>Worst itch during sleep hours</td>
<td>4.7±3.7</td>
</tr>
<tr>
<td>Worst itch during awake hours</td>
<td>5.0±3.4</td>
</tr>
<tr>
<td>Worst skin pain</td>
<td>4.1±3.5</td>
</tr>
<tr>
<td>Worst skin cracking</td>
<td>4.6±3.3</td>
</tr>
<tr>
<td>Worst pain caused by skin cracking</td>
<td>4.0±3.4</td>
</tr>
<tr>
<td>Worst dry skin</td>
<td>5.4±3.4</td>
</tr>
<tr>
<td>Worst skin flaking</td>
<td>4.4±3.6</td>
</tr>
<tr>
<td>Worst rash</td>
<td>4.9±3.4</td>
</tr>
<tr>
<td>Worst skin thickening</td>
<td>4.2±3.4</td>
</tr>
<tr>
<td>Worst skin bleeding</td>
<td>3.0±3.3</td>
</tr>
<tr>
<td>Worst skin oozing</td>
<td>3.0±3.3</td>
</tr>
</tbody>
</table>

AD-Derm-TSS-7= 7-item total symptom based on questions 1-7. ADerm-TSS-11 score = 11-item total symptom based on questions 1-11. The ADerm-SS comprises 11 questions assessing experience of symptoms over the previous 24 hours. Each question displays a rating scale ranging from 0 (no symptom) to 10 (worst experience of symptom).

AD = atopic dermatitis; SD = standard deviation. ADerm-IS = Atopic Dermatitis Impact Scale.

Figure 4. The impact of AD on anxiety and/or depression according to HADS questionnaire. HADS scores ranged from 0 to 21 for both the subscales (anxiety and depression), with 0-7 = normal, 8-10 = borderline abnormal (anxiety or depression related symptoms), and ≥11 indicating abnormal (ie clinically relevant depression or anxiety). Data are presented as %. AD = atopic dermatitis; HADS = Hospital Anxiety (HADS-A) and Depression (HADS-D) Scale.
patients were affected by disturbed sleep experienced severe itching and markedly worse QoL. Over half of patients were assessed (by a dermatologist) as having moderate-severe disease corresponding to a similar proportion of patients receiving systemic treatment. However, in our cohort, we also observed long delays in diagnosis (~2 years), diagnosis to first treatment (~10 years) and to first systemic treatment (~19 years), pointing towards an important unmet need in the awareness of this skin disorder and the appropriate therapeutic management of these difficult-to-treat patients.

A recent nationwide campaign by The Italian Society of Dermatology and Venereology, provided direct access to 27 dermatologic centers dedicated to the management of AD and it was revealed that as many as 35% of patients received an incorrect diagnosis, almost 32% of patients were untreated (either with topical or systemic agents) whereas 44.3% used routine topical compounds, similar to the proportion in our study [22]. However, although mean EASI was similar in this cohort compared to our study (11.2), only 21.5% of patients had moderate-to-severe AD compared to ~55% in our study, where we specifically selected these patients. It is widely accepted that there is an unmet need in the management of AD and recent expert consensus has endeavored to provide guidance in this regard [6] in addition to recently published guidelines [3].

As well as studies undertaken in Italy, data are also available from other large real-life studies evaluating the burden and treatment patterns in AD patients from different countries [11,13,44]. Collectively, these studies and ours, reveal that patients with moderate-to-severe AD report significant disease burden, highlighting unmet treatment needs, with particularly attention focused on the lack of/underuse of systemic treatments.

Although not available at the time the present study was undertaken, it is worth noting that in recent years, other novel systemic therapies are available that have been shown to be effective in the management of pruritus [45-47]. Further studies are needed to understand how and to what extent novel targeted systemic therapy can improve patient reported outcomes in moderate-severe AD.

Strengths and Limitations

This was a cross-sectional observational study, and the long-term effects or trends were therefore not assessed. However, the sample size of 118 patients allowed us to provide a detailed snapshot of the current real-life management and patient-centered perspective of their disease burden in Italy.

This study assumed that most patients with moderate-to-severe AD would attend dermatology clinics or underwent office visits over a period of 6 months. Patients attending a routine visit were enrolled consecutively over a 6-month period, thereby reducing the potential for selection bias.

Patients were required to describe their sleep and QoL over the previous week, thereby introducing the potential for recall bias. In general, a major limitation of population-based studies of the burden of AD is that they solely rely on patient responses.

Strengths of our study lie in the multicenter design of current real-life management and treatment of adult patients with moderate-to-severe AD. Our findings grant a unique and in-depth perspective of the disease burden experienced by these patients.

Conclusions

This real-life study highlights the impact of moderate-to-severe AD experienced by patients, a burden that is extensive and varied. Besides physical symptoms such as pain and itching, patients also experience a negative impact of AD on their QoL as reflected by disturbed sleep, reduced workability, out-of-pocket costs, increased anxiety/depression, and reduced ability to carry out normal daily activities. Delays in diagnosis to first treatment and to first systemic therapy and a high proportion of patients still receiving topical treatment (44.9%) may explain in part why approximately one-quarter of patients were not satisfied with their current treatment. An awareness of the wide ranging and extensive burden from this chronic inflammatory illness are paramount in order to make important steps towards improving patient QoL.

References

5. Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic
Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatology. 2022;158(4):404-413. DOI:10.1001/jamadermatol.2022.0029. PMID: 35262646. PMCID: PMC9808226.


